Why carry out this study?

Nonselective β blockers (NSBBs), which are recommended for the primary and secondary prophylaxis of esophageal variceal bleeding in cirrhotic patients, may be associated with the development of portal venous system thrombosis (PVT).

The role of long-term use of NSBBs in progressing thrombosis remains unclear.

What was learned from the study?

There was a higher incidence of progressing thrombosis in cirrhotic patients who received NSBBs than in those who did not receive NSBBs.

NSBBs might facilitate the progression of PVT in cirrhosis. The benefits and risks of NSBBs in the management of liver cirrhosis should be fully weighed.